SynthesisAntimicrobial resistance and infection control2022
Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021).
Synthesis in Antimicrobial resistance and infection control, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 3 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- The impact of influenza and pneumococcal vaccination on antibiotic use: an updated systematic review and meta-analysis.Antimicrobial resistance and infection control · 2023Pooled it
- Pooled it
- Global characteristics and trends in research onFrontiers in microbiology · 2023Pooled it
- Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.The Lancet. Infectious diseases · 2023Trial
- Predictors of In-Hospital Mortality Among Hospitalized Colistin-Treated Patients at a Tertiary Urology-Nephrology Referral Center.Antibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial stewardship challenges during the COVID-19 pandemic: implications of antibiotic overuse and antimicrobial resistance.Arhiv za higijenu rada i toksikologiju · 2026Review
- Transcriptome-Integrated Metabolic Modeling Identifies Candidate Metabolic Adjuvants in Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Changes in the Epidemiology of Multidrug-Resistant Organisms During the COVID-19 Pandemic: A Six-Year Retrospective Study at a Tertiary Care Hospital in Northeastern Thailand.Medical sciences (Basel, Switzerland) · 2026Observational
- Physicians' perspectives on the perceived increase in respiratory infections post-COVID-19 in Pakistan: a qualitative study.BMC infectious diseases · 2026Article
- Amino acid appended supramolecular self-associating amphiphiles demonstrate dual activity against both MRSA and ovarian cancer.Chemical science · 2026Article
- The effects of bioisostere substitution on the antimicrobial and physicochemical properties of supramolecular self-associating amphiphiles.RSC medicinal chemistry · 2026Article
- Monitoring the Burden ofAntibiotics (Basel, Switzerland) · 2026Article
- Anti-staphylococcal activity of soil-derived Penicillium citrinum extract.BMC microbiology · 2026Article
- SARS-CoV-2 Infection disrupts lower respiratory tract microbiome function and interactions.BMC microbiology · 2026Article
- From Host-Derived Pressures to the Environmental Anti-Antimicrobial Peptides Resistome: Mechanisms, Reservoirs and Implications for Therapeutic Peptide Design.Marine drugs · 2026Review
- Antimicrobial resistance within the one health lens: global drivers, mechanisms and public health policy gaps in low resource settings.Frontiers in cellular and infection microbiology · 2026Review
- Antimicrobial resistance before and after the COVID-19 pandemic in Northern Brazil.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Secondary infection in severe COVID-19 patients: clinical and microbial patterns at a tertiary hospital in Vietnam.BMC infectious diseases · 2025Article
- Environmental contamination of carbapenem-resistant gram-negative bacteria away from isolated patients in intensive care unit: a comprehensive surveillance study.Scientific reports · 2025Article
- Dicarboxylate and dicarboxylic acid appended supramolecular self-associating amphiphiles as antimicrobial agents against high priority bacterial pathogens.Organic & biomolecular chemistry · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundPneumonia from SARS-CoV-2 is difficult to distinguish from other viral and bacterial etiologies. Broad-spectrum antimicrobials are frequently prescribed to patients hospitalized with COVID-19 which potentially acts as a catalyst for the development of antimicrobial resistance (AMR).
objectivesWe conducted a systematic review and meta-analysis during the first 18 months of the pandemic to quantify the prevalence and types of resistant co-infecting organisms in patients with COVID-19 and explore differences across hospital and geographic settings.
methodsWe searched MEDLINE, Embase, Web of Science (BioSIS), and Scopus from November 1, 2019 to May 28, 2021 to identify relevant articles pertaining to resistant co-infections in patients with laboratory confirmed SARS-CoV-2. Patient- and study-level analyses were conducted. We calculated pooled prevalence estimates of co-infection with resistant bacterial or fungal organisms using random effects models. Stratified meta-analysis by hospital and geographic setting was also performed to elucidate any differences.
resultsOf 1331 articles identified, 38 met inclusion criteria. A total of 1959 unique isolates were identified with 29% (569) resistant organisms identified. Co-infection with resistant bacterial or fungal organisms ranged from 0.2 to 100% among included studies. Pooled prevalence of co-infection with resistant bacterial and fungal organisms was 24% (95% CI 8-40%; n = 25 studies: I
conclusionsDuring the first 18 months of the pandemic, AMR prevalence was high in COVID-19 patients and varied by hospital and geography although there was substantial heterogeneity. Given the variation in patient populations within these studies, clinical settings, practice patterns, and definitions of AMR, further research is warranted to quantify AMR in COVID-19 patients to improve surveillance programs, infection prevention and control practices and antimicrobial stewardship programs globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.